Vertex Pharmaceuticals Incorporated (VRTX)
VRTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$485.22
-4.30% on the day
Market cap
$123.0B
Large cap
Revenue · 2025
$12.0B
+8.9% on 2024
Net income · 2025
$4.0B
32.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | VRTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1991 |
| SEC CIK | 0000875320 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | MA |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $12.0B |
| Net income | $4.0B |
| Operating income | $4.2B |
| Net margin | 32.9% |
| Operating margin | 34.8% |
| Revenue growth | +8.9% |
| Cash | $5.1B |
| Total assets | $25.6B |
| P/E (computed) | 31.1× |
| P/S (computed) | 10.2× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2025-02-13 |
| Latest annual report | 10-K | 2026-02-13 |
| Latest quarterly / interim | 10-Q | 2026-08-04 |
| Latest current report | 8-K | 2026-09-01 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -1.4% |
| 1 month | -3.1% |
| 3 months | +2.6% |
| Year to date | +10.0% |
| 1 year | +22.4% |
| From 52-week high | -10.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | $56.67 | -1.58% | $115.8B |
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
| GSK | GSK plc | $46.27 | -1.39% | $93.6B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
| NVO | Novo Nordisk A/S | $38.06 | -1.35% | $168.5B |
| ABT | Abbott Laboratories | $102.61 | +0.78% | $177.6B |
| REGN | Regeneron Pharmaceuticals Inc. | $753.12 | -1.27% | $77.5B |
| AZN | AstraZeneca PLC | $155.82 | -1.58% | $241.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier